The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Jul. 29, 2025
Filed:
Apr. 04, 2018
Applicants:
Barinthus Biotherapeutics North America, Inc., Germantown, MD (US);
The United States of America, As Represented BY the Secretary, Department of Health and Human Services, Office of Technology Transfer, National Institute of Health, Bethesda, MD (US);
Inventors:
Geoffrey Martin Lynn, Baltimore, MD (US);
Andrew Scott Ishizuka, Washington, DC (US);
Assignees:
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 39/385 (2006.01); A61K 31/33 (2006.01); A61K 31/395 (2006.01); A61K 31/40 (2006.01); A61K 31/435 (2006.01); A61K 38/02 (2006.01); A61K 38/03 (2006.01); A61K 39/00 (2006.01); A61K 39/12 (2006.01); A61K 39/39 (2006.01); C07K 4/00 (2006.01); C07K 17/00 (2006.01); C07K 17/06 (2006.01); C07K 17/08 (2006.01); A61K 38/10 (2006.01); A61K 38/26 (2006.01);
U.S. Cl.
CPC ...
A61K 39/385 (2013.01); A61K 31/33 (2013.01); A61K 31/395 (2013.01); A61K 31/40 (2013.01); A61K 31/435 (2013.01); A61K 38/02 (2013.01); A61K 38/03 (2013.01); A61K 39/0011 (2013.01); A61K 39/12 (2013.01); A61K 39/39 (2013.01); C07K 4/00 (2013.01); C07K 17/00 (2013.01); C07K 17/06 (2013.01); C07K 17/08 (2013.01); A61K 38/10 (2013.01); A61K 38/26 (2013.01); A61K 2039/55555 (2013.01); A61K 2039/57 (2013.01); A61K 2039/6093 (2013.01); A61K 2039/627 (2013.01); A61K 2039/64 (2013.01); A61K 2039/70 (2013.01); C07K 2318/00 (2013.01);
Abstract
The present disclosure relates to novel peptide-based vaccines, methods of manufacturing the novel peptide-based vaccines and uses thereof for delivering peptide antigens to induce an immune response, and in particular a T cell response to a subject.